DKCM
NAUT icon

Davidson Kempner Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Davidson Kempner Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-134,427
Closed -$1.83M – 598
2021
Q1 		$1.83M Sell
134,427
-115,573
-46% -$1.6M 0.02% 315
2020
Q4 		$2.71M Buy
250,000
+65,627
+36% +$691K 0.03% 212
2020
Q3 		$1.99M Buy
+184,373
New +$1.97M 0.03% 201

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Davidson Kempner Capital Management's NAUT Position: Q2 2021 in Review

Davidson Kempner Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q2 2021, closing a stake of 134,427 shares — an estimated $1.83M sold.

Davidson Kempner Capital Management first reported a position in NAUT in Q3 2020 and held it in 3 quarters. The position peaked at $2.71M in Q4 2020. 56 funds tracked by Wall St. Rank hold NAUT as of Q2 2021.

  • Davidson Kempner Capital Management reported no remaining Nautilus Biotechnolgy position as of Q2 2021 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 134,427 Nautilus Biotechnolgy shares in Q2 2021, an estimated $1.83M.
  • Davidson Kempner Capital Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 3 quarters.
  • Davidson Kempner Capital Management's Nautilus Biotechnolgy position peaked at $2.71M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2021.

Based on Davidson Kempner Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.